LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Variant Gene Expression Linked to Motor Function Decline in Parkinson’s Disease

By LabMedica International staff writers
Posted on 30 May 2012
Print article
Results of a population study have shown that expression levels of the SNCA gene, which encodes alpha-synuclein protein, are directly related to the rate of decline of motor function in patients with Parkinson’s disease.

The SNCA gene is a well-known risk factor for Parkinson's disease, and higher levels of alpha-synuclein protein are associated with greater disease severity in familial cases of Parkinson's disease. Furthermore, postmortem studies have shown that expression varies with different SNCA genetic variants.

To study the role of SNCA variants in Parkinson’s disease investigators at the University of California, Los Angeles (USA observed a group of 233 Parkinson’s disease patients over a period averaging 5.1 years for motor symptom changes employing the Unified Parkinson’s Disease Rating Scale (UPDRS).

They reported in the May 15, 2012, online edition of the journal PLoS ONE that carriers of the SNCA variant Rep1 263bp had a four-fold higher risk of faster motor decline than patients carrying the rs356165 variant. An even stronger trend in progression toward motor decline was apparent in patients having both variants. While this was a relatively small study, with only 233 patients, the effects observed by the investigators were actually quite large.

“When doctors currently see Parkinson's disease patients, they cannot predict how rapidly their motor function will deteriorate - how quickly, for instance, they will reach a point when they need a wheelchair or other aids,” said senior author Dr. Jeff Bronstein, professor of neurology at the University of California, Los Angeles. “But if our results are confirmed, these gene variants can now identify patients who are likely to have faster progression.”

Being able to identify patients with the tendency for faster motor decline is expected to aid in the search for drugs to treat Parkinson’s disease. These individuals should respond to beneficial drugs earlier, thereby shortening the time required to evaluate drug performance.

Related Links:
University of California, Los Angeles


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more